Exchange: NYSEArca·Updated 04:10 PM EST

THNR News

News
all
press releases
4 Healthcare ETFs to Tap Into Eli Lilly's Post-Q3 Earnings Rally
Eli Lilly's post-Q3 earnings rally highlights its surging drug demand. Discover 4 healthcare ETFs offering LLY exposure.
Zacks
4 Healthcare ETFs to Tap Into Eli Lilly's Post-Q3 Earnings Rally
Eli Lilly's post-Q3 earnings rally highlights its surging drug demand. Discover 4 healthcare ETFs offering LLY exposure.
Zacks
More News
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
Zacks
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
Zacks
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Zacks
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
Zacks
Novo Nordisk's FDA nod for higher-dose Wegovy could boost healthcare ETFs' appeal, offering diversified exposure to the obesity drug market.
Zacks
Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.
Stocktwits
Novo Nordisk slides 15% on a cautious 2026 sales outlook, but buybacks, leadership moves and Wegovy expansion put its ETFs in focus.
Zacks
Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is accepted.
Stocktwits
Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.
Stocktwits

Advertisement|Remove ads.